HK stocks surge | Akeso (09926) rose more than 4% in the afternoon, experts are bullish on the success rate of Eveloce overseas, with safety as a key advantage.

Akeso (09926) rose more than 4% in the afternoon. As of press time, it rose by 4.11%, at HKD 38, with a transaction amount of 0.154 billion Hong Kong dollars.

Zhitong Finance01:38 ET

Brokerage Focus: Bocom Intl Reiterates Buy Rating on Akeso (09926), citing HARMONi-A Trial Overall Good Safety.

According to a research report released by Bocom Intl, Akeso (09926) recently held an investor meeting and invited the principal investigator of the Phase III HARMONi-A trial (using ivosidenib to treat EGFR-TKI resistant non-small cell lung cancer) to provide further insights. Experts believe that the probability of achieving significant OS benefit in the global HARMONi trial is greater. Overall safety was good in the HARMONi-A trial, with a controllable incidence of Grade 3 or higher TRAEs (treatment group vs. placebo group: 54.0% vs. 42.9%). The bank reaffirmed its buy rating with a target price of HKD 70.

金吾財訊20:53 ET

Akeso (09926.HK) appointed Zhang Peng as an executive director.

On July 1st, Gelunhui announced that Akeso (09926.HK) will have changes to its board of directors effective June 30th, 2024: Xia Yu has resigned as an executive director, Zhou Yi has resigned as a non-executive director, and Zhang Peng has been appointed as an executive director.

Gelonghui FinanceJul 1 07:04 ET

Akeso, Inc. Reveals Board of Directors Structure

TipRanksJul 1 06:49 ET

Express News | Akeso - Xia Yu Has Resigned as an Executive Director

ReutersJul 1 06:27 ET

Express News | Akeso - Zhou Yi Has Resigned as a Non-Executive Director

ReutersJul 1 06:26 ET